托莫西汀的最新安全警示托莫西汀(Strattera)是美国礼来公司生产的用于治疗注意力涣散型多动症的药物,自2002年在美国首次上市后,目前已创下近2 000万名美国患者用药纪录,在6 000多例的临床试验中,未发现有肝毒性报告。日前临床有2例严重肝损害的报道,1例为10多岁,另1例为成人, The latest safety warning of tomoxetine Strattera is a drug developed by Eli Lilly and Company for the treatment of attention deficit hyperactivity disorder in the United States. Since its initial public offering in the United States in 2002, Strattera has now hit nearly 20 million US patient medication records, in more than 6,000 clinical trials, no liver toxicity was found. Recently, there are 2 cases of severe liver damage reported in the clinic, 1 case of more than 10 years old, and the other 1 case of adult,